D.R. Horton
DHI
Lennar Corp
LEN
KB Home
KBH
Petroleo Brasileiro SA Petrobras
PBR
Ecopetrol
EC
US Stock MarketDetailed Quotes
CASI CASI Pharmaceuticals
- 2.2400
- +0.0400+1.82%
Close Mar 10 16:00 ET
34.70MMarket Cap-1.00P/E (TTM)
2.3300High2.2000Low4.73KVolume2.2000Open2.2000Pre Close10.57KTurnover0.06%Turnover RatioLossP/E (Static)15.49MShares7.670052wk High2.51P/B17.57MFloat Cap2.050052wk Low--Dividend TTM7.85MShs Float11137.4899Historical High--Div YieldTTM5.91%Amplitude1.4500Historical Low2.2350Avg Price1Lot Size
Trending Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
CASI Pharmaceuticals Stock Forum
CASI Announces First Patient Dosed in Phase 1/2 Clinical Trial of CID-103 in Immune Thrombocytopenia
Monday, 6th January at 8:00 am
BEIJING, CHINA / ACCESSWIRE / January 6, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ: CASI), a biopharmaceutical company specializing in the development and commercialization of innovative therapeutic and pharmaceutical products announced that the first patient has been dosed in the Phase 1/2 trial to evaluate the safety and tolerab...
📊⚡️📊
CASI Pharmaceuticals Receives CTA Approval From China's NMPA for CID-103 in Immune Thrombocytopenia
CASI Pharmaceuticals (NASDAQ:CASI) has received Clinical Trial Application (CTA) approval from China's NMPA to conduct a phase 1/2 study of CID-103 in adult patients with chronic Immune Thrombocytopenia (ITP). The China study is part of a global study previously approved by the US FDA in May 2024. CID-103 is a fully human IgG1 anti-CD38 monoclonal antibody that...
$MicroCloud Hologram (HOLO.US)$ $Loop Media (LPTV.US)$ $CASI Pharmaceuticals (CASI.US)$ $Petco Health and Wellness (WOOF.US)$ $Clearmind Medicine (CMND.US)$ $Innovative Eyewear (LUCY.US)$
📊⚡️📊
No comment yet